BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer (BC)
2016 ◽
Vol 32
(5)
◽
pp. 959-965
◽
2019 ◽
Vol 174
(3)
◽
pp. 719-729
◽
2019 ◽
2020 ◽
2016 ◽
Vol 4
(4)
◽
pp. 648-654
◽